TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Prescient Therapeutics Limited ( (AU:PTX) ) just unveiled an update.
Prescient Therapeutics Limited announced a change in the director’s interest, specifically regarding Dr. Gavin Shepherd. The change involves the acquisition of 1,213,787 unlisted options exercisable at $0.10, expiring on 17 November 2029. This issuance of options was approved by shareholders at the company’s Annual General Meeting. Such changes in director interests can influence stakeholder perceptions and reflect strategic decisions aligned with the company’s growth and operational objectives.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited operates in the biotechnology industry, focusing on the development of targeted therapies for cancer treatment. The company is dedicated to advancing its pipeline of novel cancer drugs, aiming to improve patient outcomes and address significant unmet medical needs in oncology.
Average Trading Volume: 934,319
Technical Sentiment Signal: Hold
Current Market Cap: A$60.99M
For a thorough assessment of PTX stock, go to TipRanks’ Stock Analysis page.